Skip to content

Study · Case report or series · n = 1 · 2024

8 results

Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect.

Carris NW, Wallace S, DuCoin CG, Mhaskar R, Stern M, Bunnell B

Canadian journal of physiology and pharmacology8 Apr 2024Cited by 4 (Europe PMC)

PMID38587178 (opens in a new tab)DOI10.1139/cjpp-2023-0464 (opens in a new tab)PepBankPUB-38587178
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) facilitate weight loss. Weight regain off therapy is concerning. We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intolerance ∼13 months before starting semaglutide. During semaglutide therapy, the patient reported worsened lactose intolerance and new gluten intolerance. Food allergy/celiac testing were negative. Intolerances did not improve with semaglutide discontinuation. Six months after semaglutide discontinuation, the patient was diagnosed with small intestinal bacterial overgrowth, possibly worsened by semaglutide. Factors potentially supporting weight maintenance were early drug treatment for new-onset obesity, non-geriatric age, strength training, and diet modification. The case highlights tailoring approaches to maintain weight loss without GLP-1 RAs. Trials are needed to optimize weight maintenance strategies.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 35-year-old man, oral semaglutide was followed by 22.7 kg weight loss over 120 days.

    In plain wordsOne 35-year-old man lost 22.7 kg over 120 days on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss over 120 days
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 120 daysAs given in this study (human).

    Measurements

    Weight loss
    22.7 kg
    120 days

    Source sentences

    Summary
    We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 35-year-old man, reducing oral semaglutide from 14 mg to 7 mg daily for weight maintenance was followed by weight regain.

    In plain wordsIn one man, weight came back after the oral semaglutide dose was cut from 14 mg to 7 mg.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight regain after dose reduction
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    7 mg daily · oralAs given in this study (human).

    Measurements

    Dose
    7 mg
    daily maintenance

    Source sentences

    Summary
    At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain.
    1 context sentence
    Summary · context
    We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 35-year-old man, re-increasing oral semaglutide to 14 mg/day produced weight re-loss within 1 month.

    In plain wordsIn one man, going back to 14 mg a day of oral semaglutide was followed by weight loss within a month.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight re-loss after dose re-increase
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    14 mg/day · oral · 1 monthAs given in this study (human).

    Source sentences

    Summary
    We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month
    1 context sentence
    Summary · context
    We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days.
  4. 04HumanCase report or seriesEfficacy outcome

    In a 35-year-old man, weight was maintained for a year on oral semaglutide 14 mg/day after weight re-loss.

    In plain wordsIn one man, weight stayed stable for a year on 14 mg a day of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeWeight maintenance for a year on semaglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    14 mg/day · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year
    1 context sentence
    Summary · context
    We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days.
  5. 05HumanCase report or seriesEfficacy outcome

    In a 35-year-old man, weight loss was maintained for 6 months after oral semaglutide was discontinued.

    In plain wordsIn one man, weight stayed off for 6 months after he stopped oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeWeight maintenance after discontinuation
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We then discontinued semaglutide; weight loss was maintained for 6 months.
    1 context sentence
    Summary · context
    We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days.
  6. 06HumanCase report or seriesSafety outcome

    In a 35-year-old man, worsened lactose intolerance and new gluten intolerance were reported during semaglutide therapy; food allergy and celiac tests were negative.

    In plain wordsOne man reported worse lactose intolerance and new gluten intolerance while on semaglutide; allergy and celiac tests were negative.

    Peptide
    Semaglutide
    Outcome
    IncreaseWorsened lactose intolerance and new gluten intolerance
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    During semaglutide therapy, the patient reported worsened lactose intolerance and new gluten intolerance.
    1 context sentence
    Summary · context
    Food allergy/celiac testing were negative.
  7. 07HumanCase report or seriesSafety outcome

    In a 35-year-old man, the food intolerances did not improve after semaglutide was discontinued.

    In plain wordsIn one man, the food intolerances did not get better after he stopped semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changePersistence of intolerances after discontinuation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intolerances did not improve with semaglutide discontinuation.
    1 context sentence
    Summary · context
    During semaglutide therapy, the patient reported worsened lactose intolerance and new gluten intolerance.
  8. 08HumanCase report or seriesSafety outcome

    In a 35-year-old man, small intestinal bacterial overgrowth was diagnosed six months after semaglutide discontinuation and was possibly worsened by semaglutide.

    In plain wordsOne man was diagnosed with a gut bacteria overgrowth six months after stopping semaglutide, which the drug may have worsened.

    Peptide
    Semaglutide
    Outcome
    IncreaseSmall intestinal bacterial overgrowth
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Six months after semaglutide discontinuation, the patient was diagnosed with small intestinal bacterial overgrowth, possibly worsened by semaglutide.
    1 context sentence
    Summary · context
    We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.